Anthony S. Wierzbicki
Lister Hospital
Stevenage
Hertfordshire
SG1 4AB
UK
Name/email consistency: high
- Diagnosis and treatment of severe hypertriglyceridemia. Viljoen, A., Wierzbicki, A.S. Expert. Rev. Cardiovasc. Ther (2012)
- The ezetimibe Jonah: the trials and tribulations of an unlucky drug. Wierzbicki, A.S. Int. J. Clin. Pract. (2011)
- Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Wierzbicki, A.S., Pendleton, S., McMahon, Z., Dar, A., Oben, J., Crook, M.A., Botha, A.J. Int. J. Clin. Pract. (2011)
- HDL: who needs it? Wierzbicki, A.S. Int. J. Clin. Pract. (2011)
- Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Wierzbicki, A.S. Curr. Opin. Lipidol. (2010)
- The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Wierzbicki, A.S., Morrell, J., Hemsley, D., McMahon, Z., Crook, M.A., Wray, R. Curr. Med. Res. Opin (2010)
- Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. Hardman, T.C., Rutherford, P., Dubrey, S.W., Wierzbicki, A.S. Curr. Pharm. Des. (2010)
- Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Wierzbicki, A.S., Viljoen, A. Drug. Saf (2010)
- Interpreting clinical trials of diabetic dyslipidaemia: new insights. Wierzbicki, A.S. Diabetes. Obes. Metab (2009)
- Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Wierzbicki, A.S. Curr. Opin. Cardiol. (2009)
- Future challenges for microsomal transport protein inhibitors. Wierzbicki, A.S., Hardman, T., Prince, W.T. Curr. Vasc. Pharmacol (2009)
- SEARCHing for JUPITER: starry-eyed optimism is not warranted. Wierzbicki, A.S. Int. J. Clin. Pract. (2009)
- Vascular risk screening: possible or too much, too soon?. Wierzbicki, A.S., Reynolds, T.M. Int. J. Clin. Pract. (2009)
- Familial combined hyperlipidaemia: under - defined and under - diagnosed? Wierzbicki, A.S., Graham, C.A., Young, I.S., Nicholls, D.P. Curr. Vasc. Pharmacol (2008)
- Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Int. J. Cardiol. (2008)
- Muddy waters: more stormy SEAS for ezetimibe. Wierzbicki, A.S. Int. J. Clin. Pract. (2008)
- Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Int. J. Clin. Pract. (2008)
- Surrogate markers, atherosclerosis and cardiovascular disease prevention. Wierzbicki, A.S. Int. J. Clin. Pract. (2008)
- A fishy business: omega-3 fatty acids and cardiovascular disease. Wierzbicki, A.S. Int. J. Clin. Pract. (2008)
- Lipid-altering therapies and the progression of atherosclerotic disease. Wierzbicki, A.S. Cardiovasc. Intervent. Radiol (2007)
- Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. Wierzbicki, A.S. Biochem. Soc. Trans. (2007)
- Homocysteine and cardiovascular disease: a review of the evidence. Wierzbicki, A.S. Diab. Vasc. Dis. Res (2007)
- Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Wierzbicki, A.S. Int. J. Clin. Pract. (2006)
- Fibrates after the FIELD study: Some answers, more questions. Wierzbicki, A.S. Diab. Vasc. Dis. Res (2006)
- Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Wierzbicki, A.S., Solomon, H., Lumb, P.J., Lyttle, K., Lambert-Hammill, M., Jackson, G. Atherosclerosis (2006)
- FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Wierzbicki, A.S. Int. J. Clin. Pract. (2006)
- Statins and hypertension. Wierzbicki, A.S. J. Hum. Hypertens (2006)
- Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Wierzbicki, A.S. Curr. Med. Res. Opin (2005)
- Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Wierzbicki, A.S., Doherty, E., Lumb, P.J., Chik, G., Crook, M.A. Curr. Med. Res. Opin (2005)
- Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Turner, C.N., Crook, M.A., Marber, M.S., Gill, J. Heart (2005)
- Impaired renal function and atherosclerosis in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Curr. Med. Res. Opin (2005)
- Cardiovascular risk factors and endothelial dysfunction. Wierzbicki, A.S., Chowienczyk, P.J., Cockcroft, J.R., Brett, S.E., Watts, G.F., Jenkins, B.S., Ritter, J.M. Clin. Sci. (2004)
- Lipid-lowering therapies in development. Wierzbicki, A.S. Expert. Opin. Investig. Drugs (2004)
- Lipid-altering agents: the future. Wierzbicki, A.S. Int. J. Clin. Pract. (2004)
- Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. Wierzbicki, A.S., Mayne, P.D., Lloyd, M.D., Burston, D., Mei, G., Sidey, M.C., Feher, M.D., Gibberd, F.B. J. Lipid Res. (2003)
- Statin-fibrate combination: therapy for hyperlipidemia: a review. Wierzbicki, A.S., Mikhailidis, D.P., Wray, R., Schacter, M., Cramb, R., Simpson, W.G., Byrne, C.B. Curr. Med. Res. Opin (2003)
- New lipid-lowering agents. Wierzbicki, A.S. Expert. Opin. Emerg. Drugs (2003)
- Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Wierzbicki, A.S., Reynolds, T.M., Crook, M.A. Am. J. Cardiol. (2002)
- Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Wierzbicki, A.S., Lloyd, M.D., Schofield, C.J., Feher, M.D., Gibberd, F.B. J. Neurochem. (2002)
- Beyond LDL-C--the importance of raising HDL-C. Wierzbicki, A.S., Mikhailidis, D.P. Curr. Med. Res. Opin (2002)
- Total research productivity in a pathology discipline. Wierzbicki, A.S., Reynolds, T.M. J. Clin. Pathol. (2002)
- The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Lambert-Hammill, M., Patel, S., Morrish, Z., Lumb, P.J., Lant, A.F. Am. J. Hypertens. (2002)
- Stroke in systemic lupus erythematosus. Wierzbicki, A.S. Expert. Rev. Neurother (2002)
- Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Patel, M., Smallberger, S., Lumb, P.J., Lant, A.F. Am. J. Hypertens. (2001)
- Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Wierzbicki, A.S. Lupus (2001)
- Atorvastatin. Wierzbicki, A.S. Expert. Opin. Pharmacother (2001)
- Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease). Wierzbicki, A.S., Watt, G.F., Lynas, J., Winder, A.F., Wray, R. J. Inherit. Metab. Dis. (2001)
- Drug treatment of combined hyperlipidemia. Wierzbicki, A.S., Mikhailidis, D.P., Wray, R. Am. J. Cardiovasc. Drugs (2001)
- A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. Wierzbicki, A.S., Reynolds, T.M., Gill, K., Alg, S., Crook, M.A. J. Cardiovasc. Risk (2000)
- Identification of genetic heterogeneity in Refsum's disease. Wierzbicki, A.S., Mitchell, J., Lambert-Hammill, M., Hancock, M., Greenwood, J., Sidey, M.C., de Belleroche, J., Gibberd, F.B. Eur. J. Hum. Genet. (2000)
- Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Lambert-Hammill, M., Patel, S., Morrish, Z., Lumb, P.J., Lant, A.F. J. Hum. Hypertens (2000)
- High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Wierzbicki, A.S., Lumb, P.J., Chik, G., Crook, M.A. Am. J. Cardiol. (2000)
- Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familial and polygenic hypercholesterolaemia. Wierzbicki, A.S., Lambert-Hammill, M., Junadi, E., Lumb, P.J., Crook, M.A. J. Cardiovasc. Risk (2000)